Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
CBG: verhoogd risico op tuberculose bij pralsetinib
jun 2023 | Longoncologie, Tuberculose